Abstract:BACKGROUND: Glycogen synthase kinase (GSK)-3 beta/beta-catenin signaling regulates ischemia-reperfusion (I/R)-induced apoptosis and proliferation, and inhibition of GSK-3 beta has beneficial effects on I/R injury in the heart and the central nervous system. However, the role of this signaling in hepatic I/R injury remains unclear. The present study aimed to investigate the effects and mechanism of GSK-3 beta/beta-catenin signaling in hepatic I/R injury.METHODS: Male C57BL/6 mice (weighing 22-25 g) were pretreated with either SB216763, an inhibitor of GSK-3 beta, or vehicle. These mice were subjected to partial hepatic I/R. Blood was collected for test of alanine aminotransferase (ALT), and liver specimen for assays of phosphorylation at the Ser9 residue of GSK-3 beta, GSK-3 beta activity, axin 2 and the antiapoptotic factors Bcl-2 and survivin, as well as the proliferative factors cyclin D1 and proliferating cell nuclear antigen, and apoptotic index (TUNEL). Real-time PCR, Western blotting and immunohistochemical staining were used.RESULTS: SB216763 increased phospho-GSK-3 beta levels and suppressed GSK-3 beta activity (1880 +/- 229 vs 3280 +/- 272 cpm, P<0.01). ALT peaked at 6 hours after reperfusion. Compared with control, SB216763 decreased ALT after 6 hours of reperfusion (4451 +/- 424 vs 7868 +/- 845 IU/L, P<0.01), and alleviated hepatocyte necrosis and vacuolization. GSK-3 beta inhibition led to the accumulation of beta-catenin in the cytosol (0.40 +/- 0.05 vs 1.31 +/- 0.11, P<0.05) and nucleus (0.62 +/- 0.14 vs 1.73 +/- 0.12, P<0.05), beta-catenin further upregulated the expression of axin 2. Upregulation of GSK-3 beta/beta-catenin signaling increased Bcl-2, survivin and cyclin D1. Serological and histological analyses showed that SB216763 alleviated hepatic I/R-induced injury by reducing apoptosis (1.4 +/- 0.2% vs 3.6 +/- 0.4%, P<0.05) and enhanced liver proliferation (56 +/- 8% vs 19 +/- 4%, P<0.05).CONCLUSION: Inhibition of GSK-3 beta ameliorates hepatic I/R injury through the GSK-3 beta/beta-catenin signaling pathway.

Inhibition of GSK-3β Ameliorates Hepatic Ischemia-Reperfusion Injury Through GSK-3β/β-catenin Signaling Pathway in Mice